BiotechTube
Home/PEP-Therapy/Jennifer Sengenès, PhD
JS

Jennifer Sengenès, PhD

Head of Strategy and Development

PEP-Therapy

Therapeutic Areas

Oncology

PEP-Therapy Pipeline

DrugIndicationPhase
PEP-010Recurrent and/or metastatic solid tumors (including pancreatic cancer)Phase 1a/b

Leadership Team at PEP-Therapy

AP
Antoine Prestat
Co-founder and CEO
HA
Hatem Azim, MD, PhD
Chief Medical Officer
LD
Laura Dadon, PharmD
Head of Drug Development
DG
Diego Germini, PhD
Head of Research
View full PEP-Therapy profile